Opdivo 2016 report




Published July 2017 • 27 Pages

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Opdivo through personal promotion in 2016 and how does this compare to its peer set in the Head and Neck Cancer, Hodgkin Lymphoma, Melanoma, Non-Small Cell Lung Cancer, and Renal Cancer markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
  • How does BMS’s depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, Internal Medicine, Radiation Oncology, and Diagnostic Radiology) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Opdivo throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most detailed prescribers and top paid speakers for Opdivo in 2016?

Data Sources and Methodology:

  • MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available – covering payments to more than 900,000 U.S. healthcare professionals.
  • Over 30,200 paid interactions across 7,000 physicians made on behalf of Opdivo were carefully examined to support our analysis. In addition, interaction data from 30 peer products (e.g. Abraxane, Adcetris, Afinitor, Alecensa, Alimta, Avastin, Cabometyx, Cotellic, Cyramza, Erbitux, Gilotrif, Imlygic, Inlyta, Intron A, Iressa, Keytruda, Mekinist, Nexavar, Portrazza, Sutent, Sylatron, Tafinlar, Tagrisso, Tarceva, Tecentriq, Torisel, Votrient, Xalkori, Zelboraf, and Zykadia ) was leveraged to provide benchmarking and market insights.